Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Drops By 41.3%

Aileron Therapeutics, Inc. (NASDAQ:ALRNGet Free Report) was the target of a large decrease in short interest in June. As of June 15th, there was short interest totalling 140,400 shares, a decrease of 41.3% from the May 31st total of 239,200 shares. Based on an average daily trading volume, of 110,200 shares, the short-interest ratio is currently 1.3 days. Approximately 0.7% of the company’s stock are sold short.

Insider Activity

In related news, major shareholder Of Texas/Texas Am I. University sold 9,342 shares of the company’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $3.25, for a total value of $30,361.50. Following the completion of the sale, the insider now owns 1,753,156 shares in the company, valued at approximately $5,697,757. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, major shareholder Of Texas/Texas Am I. University sold 9,342 shares of the company’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $3.25, for a total transaction of $30,361.50. Following the transaction, the insider now directly owns 1,753,156 shares of the company’s stock, valued at approximately $5,697,757. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Of Texas/Texas Am I. University sold 20,315 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $4.21, for a total transaction of $85,526.15. Following the sale, the insider now directly owns 1,779,306 shares in the company, valued at $7,490,878.26. The disclosure for this sale can be found here. In the last quarter, insiders sold 64,618 shares of company stock worth $248,685. Corporate insiders own 5.57% of the company’s stock.

Institutional Trading of Aileron Therapeutics

A hedge fund recently bought a new stake in Aileron Therapeutics stock. Sigma Planning Corp purchased a new position in shares of Aileron Therapeutics, Inc. (NASDAQ:ALRNFree Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 16,580 shares of the company’s stock, valued at approximately $51,000. Sigma Planning Corp owned about 0.34% of Aileron Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 90.89% of the company’s stock.

Aileron Therapeutics Price Performance

ALRN stock opened at $2.77 on Friday. Aileron Therapeutics has a 1-year low of $1.01 and a 1-year high of $7.42. The firm has a fifty day moving average price of $3.63 and a two-hundred day moving average price of $4.32. The firm has a market cap of $59.80 million, a price-to-earnings ratio of -0.87 and a beta of 2.11.

Aileron Therapeutics (NASDAQ:ALRNGet Free Report) last released its earnings results on Monday, May 20th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.72). As a group, analysts expect that Aileron Therapeutics will post -0.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on ALRN shares. LADENBURG THALM/SH SH raised their price target on shares of Aileron Therapeutics from $9.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, April 18th. Brookline Capital Management upgraded shares of Aileron Therapeutics to a “strong-buy” rating in a research note on Thursday, May 30th.

Read Our Latest Stock Report on Aileron Therapeutics

About Aileron Therapeutics

(Get Free Report)

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

Further Reading

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.